Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome
### Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. Some patients may be treated with 20 mg once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be adjusted upwards based on clinical response. Usual doses range from 40 mg to 80 mg twice daily. Doses > 80 mg daily should be divided and given every 12 hours.
### Pediatric Dosing
* **Erosive esophagitis (1 to 16 years):** 20 mg to 40 mg orally once daily. The choice of dose depends on body weight and severity of esophagitis.
* **Gastroesophageal reflux disease (GERD) symptoms (5 to 16 years):** 20 mg orally once daily.
* **Pathological hypersecretory conditions (1 to 16 years):** Refer to specific protocols or expert consultation as dosing is highly individualized.
### Dose Adjustments
* **Hepatic impairment:** Maximum dose of 40 mg orally once daily.
* **Renal impairment:** No dose adjustment is generally needed.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
### Adverse Effects
Common adverse effects include diarrhea, headache, dizziness, nausea, and abdominal pain. Long-term use may be associated with an increased risk of *Clostridioides difficile*-associated diarrhea, bone fractures, hypomagnesemia, vitamin B12 deficiency, and possibly renal impairment.
### Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir).
* **Methotrexate:** PPIs may increase methotrexate levels, especially at high doses. Consider temporary interruption of pantoprazole.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs like clopidogrel, although clinical significance can be variable.
### Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures, arrhythmias), especially with prolonged use (>1 year).
* Monitor for bone mineral density in patients at risk for osteoporosis.
* Consider monitoring vitamin B12 levels in patients with prolonged therapy.
### Clinical Pearls
* Pantoprazole is available in both oral and intravenous formulations.
* Oral pantoprazole is generally taken 30 to 60 minutes before a meal.
* For patients who cannot swallow whole tablets, pantoprazole delayed-release orally disintegrating tablets can be used, or the delayed-release tablets can be dispersed in applesauce or mixed with juice. Do not crush or chew.
* Intravenous administration requires reconstitution and dilution.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols before initiating or adjusting therapy.*
